ANNX vs. BMEA, HRTX, KRRO, MRSN, LXRX, NGNE, CRBP, ESPR, PEPG, and RVNC
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Biomea Fusion (BMEA), Heron Therapeutics (HRTX), Korro Bio (KRRO), Mersana Therapeutics (MRSN), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
Annexon received 12 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 73.33% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
In the previous week, Annexon had 16 more articles in the media than Biomea Fusion. MarketBeat recorded 18 mentions for Annexon and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.58 beat Annexon's score of 0.53 indicating that Biomea Fusion is being referred to more favorably in the news media.
Annexon's return on equity of -61.17% beat Biomea Fusion's return on equity.
96.7% of Biomea Fusion shares are owned by institutional investors. 19.1% of Annexon shares are owned by insiders. Comparatively, 26.3% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500.
Annexon currently has a consensus target price of $14.14, indicating a potential upside of 214.29%. Biomea Fusion has a consensus target price of $53.25, indicating a potential upside of 302.19%. Given Biomea Fusion's higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Annexon.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
